Third Harmonic Bio Inc.

NASDAQ THRD

Data sourced from

and

Daily

Download Data

Third Harmonic Bio Inc. Enterprise Value (EV) on June 03, 2024

Third Harmonic Bio Inc. Enterprise Value (EV) is NA on June 03, 2024, a NA change year over year. Enterprise Value is a measure of a company's total value, including both its equity and debt. It represents the theoretical takeover price of a company and is often used in valuation methods. Enterprise value is calculated as the sum of a company's market capitalization, total debt, and subtracting its cash and short-term investments.

Third Harmonic Bio Inc. 52-week high Enterprise Value (EV) is NA on June 03, 2024, which is NA below the current Enterprise Value (EV).
Third Harmonic Bio Inc. 52-week low Enterprise Value (EV) is NA on June 03, 2024, which is NA below the current Enterprise Value (EV).
Third Harmonic Bio Inc. average Enterprise Value (EV) for the last 52 weeks is NA.

NASDAQ: THRD

Third Harmonic Bio Inc.

CEO	Ms. Natalie C. Holles
IPO Date	Sept. 14, 2022
Location	United States
Headquarters	300 Technology Square, Cambridge, MA, United States, 02139
Employees	31
Sector	Healthcare
Industry	Biotechnology

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Key trends